Wire · opportunities
FDA setback and probe pressure ABL Bio as pipeline progress offers rebound hope
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 September 2026 · Fusion42 review
ABL Bio faces FDA delays for its drug tovetissimig after a recommendation for additional clinical trials, while also undergoing a financial probe for alleged insider trading; however, other pipeline candidates like jivastomig advance, offering potential for recovery.
This Wire brief sits within Fusion42's coverage of Biotech, and 1 source has reported it.
◆ ◆ The Wire takeaway
You face a regulatory roadblock delaying tovetissimig’s approval and royalty revenue. Shift focus to advancing other clinical assets like jivastomig to maintain business momentum while navigating regulatory and financial scrutiny.
◆ Coverage
1 source · 27 Sep 2026
◆ Related on Wire
◆ Topics